Study participants
neuropathy, allergy, CIPN, chronic kidney disease5, breast cancer3, dermatopathy
NEUROPATHY, BREAST CANCER, ALLERGY, RAYNAUD PHENOMENON, ONCOLOGY, RECURRENT BREAST CANCER, COLD
Participants will undergo screening tests to assess their eligibility according to the inclusion and exclusion criteria below.The inclusion criteria are as follows:1. Patients aged ≥ 19 years but ˂ 70 years2. Those with stages II–III breast cancer3. Those without distant metastasis4. Those scheduled to be receiving adjuvant or neoadjuvant paclitaxel for at least 12 weeks5. Those who provided informed consent6. Those with an Eastern Cooperative Oncology Group performance status ≤ 2 (Karnofsky ≥ 60%)The exclusion criteria are as follows:1. Patients with recurrent breast cancer2. Those who previously received treatment that could cause neuropathy, e.g., taxane- or platinum-based chemotherapy and anti-tubulin and proteasome inhibitor treatments3. Those with a history of neuropathy4. Those with chronic kidney disease5. Those with the Raynaud phenomenon6. Those with peripheral vascular disease or peripheral arterial ischemia7. Those with cold intolerance8. Those with an allergy to natural rubber, latex, or surgical gloves9. Those who have dermatopathy, wound, or musculoskeletal problems of the hands at enrollment10. Those taking current medications that may mitigate CIPN, including duloxetine; gabapentin/pregabalin; topical amitriptyline, ketamine, baclofen; oral cannabinoids; tricyclic antidepressants; and ganglioside-monosialic acid [